Overview

VS-6766+Abema+Fulv in Met HR+/HER- BC

Status:
Not yet recruiting

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: - VS-6766 - Abemaciclib - Fulvestrant

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Adrienne G. Waks

Collaborators:

Eli Lilly and Company
Verastem Oncology

Treatments:

Fulvestrant